Monte Rosa Therapeutics (NASDAQ:GLUE) Issues Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Monte Rosa Therapeutics (NASDAQ:GLUE) released its earnings results on Thursday. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06), FiscalAI reports. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 52.22%. The business had revenue of $4.21 million for the quarter, compared to analyst estimates of $10.95 million.

Monte Rosa Therapeutics Stock Performance

Shares of NASDAQ:GLUE traded down $0.42 during mid-day trading on Friday, hitting $19.39. The stock had a trading volume of 547,092 shares, compared to its average volume of 819,558. The company has a market cap of $1.64 billion, a PE ratio of -13.10 and a beta of 1.62. Monte Rosa Therapeutics has a 12-month low of $3.51 and a 12-month high of $25.77. The company’s 50 day moving average is $17.69 and its 200-day moving average is $17.40.

Insider Activity at Monte Rosa Therapeutics

In related news, CEO Markus Warmuth sold 5,466 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $17.92, for a total value of $97,950.72. Following the completion of the sale, the chief executive officer owned 613,471 shares in the company, valued at approximately $10,993,400.32. This represents a 0.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Philip Nickson sold 5,845 shares of the company’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $17.69, for a total transaction of $103,398.05. Following the completion of the sale, the insider owned 55,000 shares of the company’s stock, valued at approximately $972,950. This trade represents a 9.61% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 37,150 shares of company stock worth $668,694. 6.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC increased its stake in Monte Rosa Therapeutics by 56.6% in the 4th quarter. Virtu Financial LLC now owns 18,717 shares of the company’s stock valued at $293,000 after buying an additional 6,765 shares during the period. Invesco Ltd. increased its stake in Monte Rosa Therapeutics by 270.0% in the 4th quarter. Invesco Ltd. now owns 362,213 shares of the company’s stock valued at $5,680,000 after buying an additional 264,315 shares during the period. Mercer Global Advisors Inc. ADV acquired a new position in Monte Rosa Therapeutics in the 4th quarter valued at approximately $172,000. Empowered Funds LLC increased its stake in Monte Rosa Therapeutics by 218.0% in the 4th quarter. Empowered Funds LLC now owns 278,077 shares of the company’s stock valued at $4,360,000 after buying an additional 190,627 shares during the period. Finally, Voloridge Investment Management LLC acquired a new position in Monte Rosa Therapeutics in the 4th quarter valued at approximately $561,000. Institutional investors and hedge funds own 79.96% of the company’s stock.

Analyst Ratings Changes

GLUE has been the subject of several recent research reports. Piper Sandler reissued an “overweight” rating and set a $37.00 target price (up from $27.50) on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 14th. Guggenheim cut their target price on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research note on Wednesday, March 18th. Wells Fargo & Company cut their target price on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, March 18th. Wall Street Zen lowered shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, Zacks Research downgraded shares of Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 4th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.80.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.